PATH B programme for patients with hepatitis B launches in Europe

NewsGuard 100/100 Score

A pioneering educational resource, designed to improve the lives of people living with chronic hepatitis B, was launched today at an annual conference organised by Bristol-Myers Squibb in Hong Kong where 26 patient advocacy groups from 14 countries and regions gathered to discuss viral hepatitis.

The PATH B ("Patients and Professionals Acting Together for Hepatitis B") programme was developed by an international advisory board comprising people living with hepatitis B, as well as patient advocacy group representatives and leading hepatologists from across Europe. This programme is provided as an educational service by the World Hepatitis Alliance (WHA) and The European Liver Patients Association (ELPA). The programme was organised and funded by Bristol-Myers Squibb.

The European Association for the Study of the Liver (EASL) also welcomed "the scope of the information the Path B resource provides to patients".

Professor Mark Thursz, Secretary General of the European Association for the Study of the Liver commented: "This resource provides comprehensive and reliable information for patients diagnosed with hepatitis B.  I have no doubt that PATH B will help patients to be better informed, empowered and equipped to manage their treatment journey."

The core component of the PATH B programme is a patient-centric resource, PATH B - My journey with chronic hepatitis B.  This extensive interactive educational resource consists of a hepatitis B journey roadmap that guides patients through every step and aspect of hepatitis B and treatment options. The six stages of the roadmap cover key aspects of a patient's journey with essential information from diagnosis to long-term disease management.

"There is a large information gap for chronic hepatitis B patients between their initial diagnoses and the long-term management of their disease," said PATH B advisory board member, Achim Kautz, ELPA Board Member. "For the first time, this toolkit seeks to fill that unmet need for complete and reliable information that patients can depend on through every step of their disease."

An innovation contained within the PATH B resource is the online diary where patients can record notes, test results, write in medical appointments as well as any disease or treatment related problems they may experience. The resource contains also a 'View Your Progress' tool, which, for the first time, allows patients to plot their test results over time and to chart the progress of their treatment. The aim of this tool is to help patients understand their treatment, therefore aiding adherence. 

Charles Gore, President of the World Hepatitis Alliance, praised the resource: "PATH B is the first of its kind in terms of the range of patient materials available in such a portable interactive format. It really does provide practical help for patients."

The PATH B resource was also designed to facilitate better patient-physician dialogue, and to provide trustworthy information.

"As a clinician, I have seen that patients who are more knowledgeable about their disease feel empowered and in control and tend to have better outcomes," said PATH B advisory board member, Dr. Mark Wilkinson of Guy's and St Thomas' Hospital, London, UK.

Although this resource was developed primarily for patients it can also be a helpful tool for physicians to enhance dialogue with patients on disease progression, treatment and the importance of adherence and persistency.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New optimized vaccine approach targets Hepatitis C virus variability